Literature DB >> 10638964

Androgen receptor protein is down-regulated by basic fibroblast growth factor in prostate cancer cells.

M V Cronauer1, C Nessler-Menardi, H Klocker, K Maly, A Hobisch, G Bartsch, Z Culig.   

Abstract

Interactions between polypeptide growth factors and the androgen receptor (AR) are important for regulation of cellular events in carcinoma of the prostate. Basic fibroblast growth factor (bFGF), the prototype of heparin-binding growth factors, and the AR are commonly expressed in prostate cancer. bFGF diminished prostate-specific antigen protein in the supernatants of androgen-stimulated human prostate cancer cells LNCaP by 80%. In the present study, we asked whether the bFGF effect on prostate-specific antigen is preceded by action on AR expression. LNCaP cells were treated with bFGF and AR protein expression was determined by immunoblotting and ligand binding assay. bFGF down-regulated AR protein in a dose-dependent manner showing a maximal effect at 50 ng ml(-1) both in the presence or absence of dihydrotestosterone. Down-regulation of AR protein expression occurred already after 8 h of bFGF treatment and a maximal inhibition was observed 24 h after addition of bFGF to culture media. As AR expression can be reduced by an increase in intracellular calcium levels, we investigated whether the bFGF effect on AR protein is mediated by this mechanism. Calcium release from intracellular stores and store-operated calcium influx after treatment with either bFGF or calcium ionophore A 23187 were measured by single cell fluorescence technique. The ionophore A 23187 was able to induce calcium influx and an increase in cytoplasmic calcium concentration in LNCaP cells. In contrast, bFGF was incapable of eliciting a similar effect. In contrast to AR protein, AR mRNA levels were not affected by bFGF as shown by semiquantitative reverse transcription polymerase chain reaction. In summary, these studies show that bFGF is a potent negative regulator of AR protein expression in the human prostate cancer cell line LNCaP.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10638964      PMCID: PMC2363213          DOI: 10.1054/bjoc.1999.0874

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  45 in total

1.  Stimulation of C2C12 myoblast growth by basic fibroblast growth factor and insulin-like growth factor 1 can occur via mitogen-activated protein kinase-dependent and -independent pathways.

Authors:  D J Milasincic; M R Calera; S R Farmer; P F Pilch
Journal:  Mol Cell Biol       Date:  1996-11       Impact factor: 4.272

2.  Agonists, but not antagonists, alter the conformation of the hormone-binding domain of androgen receptor.

Authors:  P J Kallio; O A Jänne; J J Palvimo
Journal:  Endocrinology       Date:  1994-02       Impact factor: 4.736

3.  Signal transduction by basic fibroblast growth factor in rat osteoblastic Py1a cells.

Authors:  M M Hurley; K Marcello; C Abreu; M Kessler
Journal:  J Bone Miner Res       Date:  1996-09       Impact factor: 6.741

4.  Androgen receptors in endocrine-therapy-resistant human prostate cancer.

Authors:  T H van der Kwast; J Schalken; J A Ruizeveld de Winter; C C van Vroonhoven; E Mulder; W Boersma; J Trapman
Journal:  Int J Cancer       Date:  1991-05-10       Impact factor: 7.396

5.  Basic fibroblast growth factor-stimulated endothelial cell movement is mediated by a pertussis toxin-sensitive pathway regulating phospholipase A2 activity.

Authors:  G Sa; P L Fox
Journal:  J Biol Chem       Date:  1994-02-04       Impact factor: 5.157

6.  Activation of phosphatidylinositol 3-kinase by epidermal growth factor, basic fibroblast growth factor, and nerve growth factor in PC12 pheochromocytoma cells.

Authors:  S Raffioni; R A Bradshaw
Journal:  Proc Natl Acad Sci U S A       Date:  1992-10-01       Impact factor: 11.205

7.  Identification of 3',5'-cyclic adenosine monophosphate response element and other cis-acting elements in the human androgen receptor gene promoter.

Authors:  A Mizokami; S Y Yeh; C Chang
Journal:  Mol Endocrinol       Date:  1994-01

8.  Modulation of calcium current, intracellular calcium levels and cell survival by glucose deprivation and growth factors in hippocampal neurons.

Authors:  B Cheng; D G McMahon; M P Mattson
Journal:  Brain Res       Date:  1993-04-02       Impact factor: 3.252

9.  Growth factor regulation of gene expression in the human prostatic carcinoma cell line LNCaP.

Authors:  P Henttu; P Vihko
Journal:  Cancer Res       Date:  1993-03-01       Impact factor: 12.701

10.  Endogenous fibroblast growth factor-1 or fibroblast growth factor-2 modulate prostate cancer cell proliferation.

Authors:  S A Shain; T Sarić; L D Ke; D Nannen; S Yoas
Journal:  Cell Growth Differ       Date:  1996-05
View more
  4 in total

1.  The evolutionary impact of androgen levels on prostate cancer in a multi-scale mathematical model.

Authors:  Steffen E Eikenberry; John D Nagy; Yang Kuang
Journal:  Biol Direct       Date:  2010-04-20       Impact factor: 4.540

2.  Inhibition of glycogen synthase kinase-3 in androgen-responsive prostate cancer cell lines: are GSK inhibitors therapeutically useful?

Authors:  Ludwig Rinnab; Stefanie V Schütz; Jeannine Diesch; Evi Schmid; Rainer Küfer; Richard E Hautmann; Klaus-Dieter Spindler; Marcus V Cronauer
Journal:  Neoplasia       Date:  2008-06       Impact factor: 5.715

3.  The transcriptional co-activator cAMP response element-binding protein-binding protein is expressed in prostate cancer and enhances androgen- and anti-androgen-induced androgen receptor function.

Authors:  Barbara Comuzzi; Leonidas Lambrinidis; Hermann Rogatsch; Sonia Godoy-Tundidor; Nikola Knezevic; Ivan Krhen; Zvonimir Marekovic; Georg Bartsch; Helmut Klocker; Alfred Hobisch; Zoran Culig
Journal:  Am J Pathol       Date:  2003-01       Impact factor: 4.307

Review 4.  Degradation and beyond: control of androgen receptor activity by the proteasome system.

Authors:  Tomasz Jaworski
Journal:  Cell Mol Biol Lett       Date:  2006       Impact factor: 5.787

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.